Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development.
[Molecular genetic characteristics of the virus isolated from patients with human acute encephalomyelitis and multiple sclerosis].
Quality improvement in neurology: Multiple sclerosis quality measures: Executive summary.
Increased Concentrations of Interleukin-33 in the Serum and Cerebrospinal Fluid of Patients with Multiple Sclerosis.
Unilateral internuclear ophthalmoplegia after minor head injury.
Chronic inflammatory demyelinating polyneuropathy associated with alopecia totalis and Sjögren syndrome.
Increased interleukin-6 correlates with myelin oligodendrocyte glycoprotein antibodies in pediatric monophasic demyelinating diseases and multiple sclerosis.
Impact of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod: Subgroup analyses of the Fingolimod Research Evaluating Effects of Daily Oral Therapy in Multiple Sclerosis (FREEDOMS) study.
A Novel Asp121Asn Mutation of Myelin Protein Zero Is Associated with Late-Onset Axonal Charcot-Marie-Tooth Disease, Hearing Loss and Pupil Abnormalities.
[Sarcoid neuropathy].
[Symptoms and neurological findings in patients with multiple sclerosis].
[Current and historical concept of neuromyelitis optica].
Environmental enrichment as a method to improve cognitive function. What can we learn from animal models?
New Perspectives in Pediatric Neurology-Multiple Sclerosis.
Health-related quality of life in multiple sclerosis: role of cognitive appraisals of self, illness and treatment.
Nerve ultrasound protocol in differentiating chronic immune-mediated neuropathies.
YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis.
[Chronic inflammatory demyelinating polyradiculoneuropathy(CIDP): Treatment and prognosis].
Cost-Utility Analysis of Natalizumab as First-Line Treatment of Highly-Active Relapsing-Remitting Multiple Sclerosis in the Brazilian Public Healthcare System.
Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi Study.
Comparison of Network Meta-Analysis and Traditional Meta-Analysis for Prevention of Relapses In Multiple Sclerosis.
A Meta-analysis of the relation between chemokine receptor 5 delta32 polymorphism and multiple sclerosis susceptibility.
Neurosarcoidosis: Clinical Features, Diagnosis, and Management.
Identifying clues to molecular etiology of multiple sclerosis in South Indian patients.
The Protective Role of HLA-DRB1(∗)13 in Autoimmune Diseases.
Pages
« first
‹ previous
…
674
675
676
677
678
679
680
681
682
…
next ›
last »